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Abstract 
Several studies have now shown that chronic myeloid leukaemia (CML) patients in deep molecular 
remission may discontinue tyrosine kinase inhibitor (TKI) treatment with a treatment free remission 
(TFR) rate of approximately 40-60%. Some factors influencing the possibility of TFR have been 
described but better tools are needed for individual prediction of long-term TFR. Herein, two 
multiplex panels were utilised to analyse a total of 162 different plasma proteins from 56 patients 
included in the TKI stopping trial EURO-SKI.1 The purpose was to identify possible plasma protein 
markers for prediction of successful TKI discontinuation and to evaluate effects of TKI discontinuation 
on plasma protein profiles. No protein biomarkers sampled before TKI discontinuation could 
separate relapse cases from non-relapse cases but some plasma proteins differed between patients 
who relapsed and those who remained in TFR when followed over time after TKI cessation. In 
conclusion, the plasma protein markers in this study could not predict relapse after TKI 
discontinuation but may be of use to understand the mechanisms involved in maintenance of TFR. 
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Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disorder arising due to the 
formation of a constitutively active tyrosine kinase (Bcr-Abl) through a translocation between 
chromosomes 9 and 22 in hematopoetic stem or progenitor cells.2 Treatment with inhibitors of the 
Bcr-Abl (tyrosine kinase inhibitors, TKIs) has during the last two decades drastically improved CML 
prognosis.3-6 However, long term TKI treatment is associated with high costs and severe adverse 
effects such as cardiovascular events.7 During recent years, several studies have shown that a 
proportion of TKI-treated patients who achieve optimal treatment responses (MR4  i e   log 
reduction in BCR-ABL1; BCR-ABL1  or better) may discontinue treatment and remain in 
treatment-free remission (TFR) (reviewed in8). It is not fully known what factors influence the 
probability of TFR but so far, reports suggest that duration of TKI treatment and deep molecular 
response (DMR) before TKI stop influence the chances of remaining in TFR.1 Also, factors related to 
the patients´ immune status seem to be of importance.9-11 Recently described factors of potential 
significance for TFR are genetic variants discovered by whole-exome sequencing12 and telomere-
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length shortening.13 However, there is still need for better prediction tools for choosing the right 
patients for stopping attempts. Easily accessible biomarkers such as plasma proteins would be a 
valuable complement for guiding decision making when TKI stopping attempts are moved in to 
clinical routine in the management of CML patients. 
We have previously shown that plasma proteomics are feasible and useful in CML patients, both for 
studying patterns of protein expression and for identifying single proteins differentially expressed 
before and after TKI treatment initiation.14 In the present paper, we use a proximity extension assay 
(PEA)-based proteomic platform to study protein expression in a patient cohort from the large TKI 
stopping study EURO-SKI.1 We studied a total of 162 plasma proteins in TKI-treated patients (n=56) 
before, at one and six months after TKI cessation, and at relapse with the primary aim of finding 
plasma protein markers predicting a successful treatment stop by comparing the markers between 
patients with and without relapse.  
  
 
2. Materials and methods 
 
2.1. Patients and samples 
The study was conducted as an exploratory sub-study of the European Stop Tyrosine Kinase Inhibitor 
Study (EURO-SKI) (ClinicalTrials.gov identifier: NCT01596114). The patients included (n=56, age range 
18-78 years) were from Finland, Norway and Sweden. All were in chronic phase and had been 
treated with TKIs for at least three years prior to inclusion in the study. As outlined in the EURO-SKI 
inclusion criteria, all patients had sustained DMR (MR4.0) for at least one year before TKI cessation. 
Relapse was defined as loss of major molecular response (MMR; BCR-ABL 0.1% on the international 
scale). Peripheral blood samples were obtained at baseline (immediately prior to TKI cessation), at 
one and six months after stopping TKIs, and at relapse. All patients gave written informed consent to 
study inclusion. The study was approved by the local ethics committees in each country and 
conducted in accordance with the Declaration of Helsinki. 
 
2.2. Plasma sample analysis and data processing 
Heparin blood was shipped to Helsinki from the participating centres. Heparin plasma was obtained 
by centrifugation at 1300 g for 10 minutes in room temperature and immediately after collection, the 
plasma was stored in -70°C. Patient samples were analysed with Olink Proseek Multiplex (Olink 
Proteomics, Uppsala, Sweden). Two different panels were used, Inflammation I (INF I) and Oncology 
II (ONC II), each containing 92 inflammation- and cancer-related protein biomarkers, respectively 
(see Supplemental Tables A1 and A2 for a complete list of all biomarkers). Olink utilizes so called 
proximity extension assay (PEA) which is based on pairs of antibodies linked to oligonucleotides with 
a slight affinity to each other. When the antibodies bind to their target protein, the oligonucleotides 
are brought in proximity and extended by a DNA polymerase, forming a new sequence that acts as a 
surrogate marker for the antigen. The new sequence is then extended by qPCR and the copy 
numbers formed are proportional to the concentration of the antigen in the sample.15 Frozen 
aliquots of patient heparin plasma samples were shipped to Olink Proteomics and analysed there 
according to the laborator s standard operating procedure  Samples ere run in duplicates  The 
limit of detection (LOD) was defined as 3xSD above assay background and values below the LOD 
were replaced by the value for the LOD for statistical analyses. If many values are replaced by the 
LOD value the natural variation in the data for that analyte decreases, which might have an impact 
on the statistical analyses. In this study, a few analytes had a large amount of values below the LOD, 
and the rest of the analytes had very few of these values. Therefore, analytes with  of values 
below the LOD were excluded from statistical analyses. The remaining analytes all had less than 10% 
of values below the LOD. Proseek Multiplex uses relative quantification and data are presented as 
normalized protein expression (NPX), which is an arbitrary unit on log2 scale. Internal and external 
controls were included in each run. Coefficients of variation (CV) values were calculated using 
linearized values (2NPX) in order to investigate platform performance, for all statistical analyses the 
log2 scale was used. 
 
2.3. Statistical analyses 
Statistical analyses were performed on log2 data which were approximately normally distributed.  
Welch s unequal ariances t-test was used to determine statistically significant differences between 
groups (relapse vs. non-relapse). Linear Mixed Effects Modelling (LMM)16 was used to investigate 
differences between groups over time and the effect of time itself (longitudinal analyses) during the 
first 6 months. With LMM the within-individual correlations are taken into account, as well as the 
order of the time points, and the baseline value is allowed to vary between individuals (random 
intercept). The group effect relapse versus non-relapse is treated as a fixed effect, and a Toepliz 
within-individual correlation structure is being used which implies that the correlation between close 
time points may differ from the correlation between time points further apart. The mean protein 
levels are estimated by a linear trend over time, and these linear trends are compared between the 
two groups. The data does not suggest any particular trend pattern, which makes a linear trend a 
reasonable choice to summarize the effect of time. Analyses of the model residuals showed that the 
model fitted the data well for all the analytes.  
 All analyses were adjusted for multiple testing using the False Discovery Rate (FDR) method of 
correction.17 The false discovery rate is the proportion of "discoveries" (significant results) that are 
actually false positives. Since we have previously explored the effects of TKI treatment on plasma 
protein profiles 14, we used a false discovery rate of 5% for analyses of TKI effects in treated patients. 
In the mixed effects model a false discovery rate of 10% was applied since this was considered an 
exploratory setting and positive results would have to be confirmed in follow-up studies which would 
reveal any false positives. Thus, using a false discovery rate of 10% is feasible in this situation. 





3.1. Platform performance and output 
On both panels, 98% of the samples met the quality control criteria. Intra-assay coefficient of 
variance (CV) values were 6% for both INF I and ONC II. Inter-assay CV values were 12% and 11% for 
INF I and ONC II, respectively. On the INF I panel, 76% of the analytes were detectable in >75% of the 
samples. On the ONC II panel, all analytes were detectable in >75% of the samples, rendering 162 
evaluable proteins in total. 
 
3.2. Patient characteristics 
Patient characteristics are summarised in Table 1. The median (range) age at diagnosis was 53.3 
(17.8-77.9) years. The male to female ratio was 31 to 25. Sokal risk group distribution was as follows: 
52% low risk (LR), 27% intermediate risk (IR), 16% high risk (HR) and 4% unknown. For the EUTOS 
score, 89% were LR, 7% HR and 4% unknown. Thus, a slightly higher proportion of patients were low 
risk as compared to a population-based cohort.6  
 At diagnosis, patients were started on treatment with imatinib (n=42), dasatinib (n=11) or 
nilotinib (n=3). At TKI stop, two patients had changed treatment from imatinib to dasatinib and two 
had changed from dasatinib to imatinib so that the frequencies of different treatments remained 
unchanged. Nine patients (5 in the relapse group and 4 in the non-relapse group) had been treated 
with interferon (IFN) alpha prior to TKI treatment. Median (range) age at TKI stop was 62.1 (23.5-
83.7) years and median TKI treatment duration was 6.1 (3.1-12.3) years. After a median (range) 
follow up of 22.9 (7.3-38.5) months, 32 patients had relapsed as defined in the methods section. 
Twenty-four relapses occurred within the first six months (early) and eight thereafter (late). At 
relapse, all patients were re-started on TKI treatment. At the end of follow up, all 32 patients had 
regained MMR and all but two had regained MR4.0. 
 
3.3. Relapse versus non-relapse 
At baseline, immediately prior to TKI discontinuation, no significant differences in protein levels were 
found b  Welch s t-test between patients who later relapsed and those who remained in TFR. 
However, when analysing data over time after TKI discontinuation with the linear mixed model 
approach, some differences between groups could be seen. The analytes that differed between 
relapse and non-relapse cases were leukaemia inhibitory factor receptor (LIF-R; LMM estimate for 
relapse -0.1838, p=0.0106), IL-15 receptor alpha (IL-15R alpha; LMM estimate for relapse -0.2136, 
p=0.0235), colony stimulating factor-1 (CSF-1; LMM estimate for relapse -0.18679, p=0.0014), 
transforming growth factor beta receptor type 2 (TGFR-2; LMM estimate for relapse -0.2672, 
p=0.0218), stem cell factor (SCF; LMM estimate for relapse -0.2221, p=0.0254) and folate receptor 
(FR) alpha (LMM estimate for relapse -0.2208, p=0.0257) (Figure 1). Thus, a significant difference 
between group means could be seen over time, with non-relapse cases having higher group means 
for all analytes mentioned above. Indi idual patients  alues were also compared to group means 
and related to relapse status. At the 1 month-time point, many relapse cases had values higher than 
the group means (between 31 and 55% for the different analytes) and no clear cut off-value could be 
found to distinguish between relapse and non-relapse cases. At the 6 month-time point, a smaller 
proportion of relapse cases had values higher than the group means (between 13 and 38%). For the 
LIF-R and TGFR-2, only one relapse case per analyte had a value above the group mean. However, no 
clear cut-off value separating relapse and non-relapse cases could be found at 6 months either. 
 Since most relapses after TKI discontinuation occur during the first 6 months, we were interested 
in finding possible biological differences between early (within the first six months) and late relapses. 
Results from baseline and month 1 for patients who relapsed were therefore compared between the 
two groups but no significant differences could be seen at any time point.  
 
3.4. Effects of TKI treatment 
Since imatinib and dasatinib are known to affect partly different signalling pathways 18, we compared 
baseline values between these two groups. However, only a few proteins (monocyte chemotactic 
protein (MCP) 4, glypican-1 (GPC1), Erb B2, Erb B4, CD207; adjusted p-values <0.05; Figure 2) were 
significantly different between imatinib- and dasatinib-treated patients with values being higher in 
imatinib-treated patients for all differing analytes.  
 After TKI discontinuation, an increase or decrease over time could be seen for a total of 39 
proteins with the LMM analysis (Table 2), while the remaining analytes did not significantly change 
over the course of six months.  
 Since prior treatment with IFN alpha has been implicated to increase the probability of TFR19, we 
evaluated possible differences in protein levels between patients who had received IFN pre-
treatment at any time point and those who had not. With reservation for unequal group sizes, no 
significant differences in protein levels could be found at any time point between patients who had 
been previously treated with IFN alpha and those who had not received such treatment. 
 
4. Discussion 
Despite increasing knowledge about clinical and biological factors influencing the probability of TFR 
after TKI discontinuation, there is still a need for better prediction tools to guide clinical decision 
making when choosing patients for TKI stopping attempts. In the present study, we performed 
plasma proteomics on 56 patients discontinuing TKIs within the EURO-SKI trial with the aim of 
identifying potential plasma protein biomarkers for relapse after TKI discontinuation.  
 No plasma proteins were significantly different between relapse and non-relapse patients before 
stopping TKI treatment and thus, no predictive plasma protein markers for successful TKI 
discontinuation could be identified. Also after TKI discontinuation, only a few plasma proteins were 
significantly different between relapse and non-relapse cases, probably reflecting that the levels of 
disease at molecular relapse are low with a low mutational profile that does not evoke T-cell 
responses or profound effects on plasma cytokine levels. The fact that NK cell-based immunity, which 
is independent of the formation of new tumour antigens, has been shown to be important for TFR10 
supports this theory. Nevertheless, six plasma proteins differed significantly between relapsing and 
non-relapsing patients after TKI discontinuation: LIF-R, IL-15R alpha, CSF-1, TGFR-2, SCF and FR alpha. 
The mean protein levels were higher in non-relapse cases for all analytes.  
 The LIF-R, upon binding of its ligand LIF, activates JAK/STAT and other signalling pathways.20 LIF-R 
has been shown to suppress metastasis of hepatocellular carcinoma and pancreatic cancer.21,22 
However, in CML, STAT signalling has been connected to leukaemia initiation and maintenance23 as 
well as TKI resistance.24 Thus, the mechanisms behind our findings remain to be elucidated but might 
involve other signalling pathways than the JAK:STAT pathway in residual malignant cells or signalling 
in other cell types such as immune cells since LIF:LIF-R signalling plays an important role in T-cell 
immunity.20  
 IL-15R alpha is a sub-unit of the IL-15 receptor that binds IL-15 to the cell surface and thereby 
supports NK-cell development.25,26 Clinical trials using IL-15 alone or in combination with NK cells 
have shown beneficial effects in both solid tumours and haematological malignancies.27 We have 
previously shown that an increased proportion of mature NK cells was associated with successful 
imatinib discontinuation10 and our current finding of higher levels of IL-15R alpha in the non-
relapsing patients might offer support for the importance of NK cells in successful TFR. 
 CSF-1 (or M-CSF; macrophage-colony stimulating factor) is important for innate immunity by its 
regulation of the development of tissue macrophages.28 In solid cancers, the expression of CSF-1 and 
presence of tumour infiltrating macrophages have been linked to poor outcome29 while less is known 
about the role of CSF-1 in leukaemia. Imatinib has off-target effects on the receptor for CSF-1, the c-
fms.30 Thus, our findings are of unclear significance but could have potential explanations both in 
immunological functions and treatment effects. 
 TGFR-2 is the receptor for TGF , which is a transcriptional regulator in hematopoietic cells and 
induces cell cycle arrest in primitive bone marrow progenitors.31 A study comparing the inhibitory 
effects of TGF  on primiti e hematopoetic cells from CML patients and health  donors found that the 
CML progenitors ere more sensiti e to TGF  mediated inhibition than their normal counterparts.32 
Low levels of TGFR-2 have been found in both CML and other myeloproliferative neoplasms.33 Thus, 
one can speculate that the lower levels of TGFR-2 that we found in relapse cases might give a 
proliferative advantage to cells that escape the negati e regulation of TGF  
 SCF, which is the ligand for receptor c-kit that is targeted by imatinib, has previously been implied 
in the pathogenesis of CML by inducing proliferation of CD34+ progenitors in vitro.34 However, SCF 
levels in serum from untreated CML patients are not different from healthy controls.35 Imatinib 
treatment has been shown to increase SCF in patients treated for gastrointestinal stromal tumours 
(GIST)36 and, in a pilot study evaluating the effects of TKI treatment on multiple plasma proteins in 
CML patients, we also found that SCF increased after treatment initiation.14 It is thus possible that 
the effect of SCF on CML cells is different in vitro and in vivo. The increase in SCF described after 
imatinib treatment might represent a compensatory mechanism to maintain normal c-kit related 
functions which might somehow be of importance for TFR. 
 FR alpha is increased in tumours of epithelial origin and might confer a growth advantage to the 
tumour by modulating folate uptake from serum.37 FR alpha expression has not been extensively 
studied in CML or other haematological malignancies and its effects in CML are to our knowledge 
unknown. However, in our previous study referred above, FR alpha increased in CML patients after 
TKI treatment initiation. 
 In conclusion, only a few differences in protein levels were seen between non-relapsing and 
relapsing cases. No predictive protein biomarkers for successful TKI discontinuation could be found. 
It could be of interest to confirm the differences between relapse and non-relapse cases in an 
experimental setting or in a bigger cohort of patients, but it is likely that plasma protein markers 
alone are not sensitive enough to predict molecular relapse. It is plausible that several different 
clinical and biological factors will need to be combined for the best prediction of which patients will 
benefit most from TKI cessation attempts. 
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Tables and figures 
Table 1. Patient characteristics (N=56) 
Age at diagnosis (years) 53.3 (17.8-77.9) 
Age at stop (years) 62.1 (23.5-83.7) 
Sex (N (%))  
Female  25 (45) 
Male 31 (55) 
Sokal score (N (%))  
LR 29 (52) 
IR 15 (27) 
HR 9 (16) 
Missing 2 (4) 
EUTOS score (N (%))  
LR 50 (89) 
HR 4 (7) 
Missing 2 (4) 
First TKI (N (%))  
Ima 42 (75) 
Dasa 11 (20) 
Nilo 3 (5) 
TKI at stop (N (%))  
Ima 42 (75) 
Dasa 11 (20) 
Nilo 3 (5) 
Total TKI duration at stop (years) 6.1 (3.1-12.3) 
Relapse, total (N (%)) 32 (57) 
Relapse, early (≤6 months) (N (%)) 24 (75) 
BCR-ABL1 ≥1% at relapse (N (%)) 3 (9) 
Regained MMR after TKI re-initiation (N (%)) 32 (100) 
Regained MR4.0 after TKI re-initiation (N (%)) 30 (94) 
Abbreviations: LR=low risk, IR=intermediate risk, HR=high risk; ima=imatinib, dasa=dasatinib, nilo=nilotinib; MMR=major 





















Hepatocyte growth factor (HGF) 0.05009 0.007848 0.09233 0.0016 
Eucaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1) 
0.03773 -0.02801 0.1035 0.0131 
Delta and notch-like epidermal growth factor-
related receptor (DNER) 
0.00803 -0.00618 0.02224 0.0057 
CD40 0.03106 -0.00372 0.06585 0.0111 
 nucleotidase (5-NT) 0.03020 -0.00573 0.06613 0.0320 
Adenosine Deaminase (ADA) 0.04524 0.01808 0.07240 <.0001 
Annexin 1 (ANXA1) 0.04215 -0.02057 0.1049 0.0089 
C-X-C motif chemokine 13 (CXCL13) 0.05079 0.006012 0.09557 0.0142 
Carbonic anhydrase 9 (CA9) -0.06850 -0.1178 -0.01925 0.0002 
Carboxypeptidase E (CPE) -0.02186 -0.04436 0.000638 0.0007 
Disintegrin and metalloproteinase domain-
contacting protein 8 (ADAM-8) 
0.03020 -0.00573 0.06613 0.0320 
Epidermal growth factor (EGF) 0.03004 -0.03263 0.09272 0.0017 
FC-receptor-like B (FCRLB) -0.01600 -0.03981 0.007811 0.0022 
Fasantigen ligand (FasL) 0.02967 0.01057 0.04877 <.0001 
Fibroblast growth factor-binding protein 1 (FGF-
BP1) 
-0.02240 -0.04886 0.004050 0.0008 
Folate receptor alpha (FR alpha) -0.02230 -0.04214 -0.00247 0.0036 
Fractalkine (CX3CL1) -0.03501 -0.05676 -0.01327 0.0096 
Furin 0.02235 0.000552 0.04414 0.0023 
Galectin 1 (Gal-1) 0.01812 0.005558 0.03069 0.0234 
Hepatocyte growth factor (HGF) 0.05009 0.007848 0.09233 0.0016 
ICOS ligand (ICOSLG) 0.01673 0.001090 0.03237 0.0040 
Integrin beta-5 (ITGB5) 0.01451 -0.00780 0.03681 0.0203 
Interleukin 10 receptor subunit beta (IL10 RB) 0.02328 0.006953 0.03961 <.0001 
Interleukin 18 receptor 1 (IL18 R1) 0.02000 -0.00229 0.04229 0.0008 
Kallikrein 14 (hK14) -0.01090 -0.04234 0.02053 0.0139 
Matrix metalloproteinase 10 (MMP10) -0.05329 -0.08039 -0.02620 0.0004 
Proto-oncogene tyrosine-protein kinase receptor 
(RET) 










Receptor tyrosine-protein kinase (Erb-B2) 0.00834 -0.00691 0.02358 0.0068 
S100-A12 (EN-RAGE) 0.07587 -0.00169 0.1534 0.0027 
TNF-related apoptosis-inducing ligand (TRAIL) 0.02462 0.009219 0.04001 <.0001 
TNFRSF1919 0.05662 0.03045 0.08278 <.0001 
Tissue factor pathway inhibitor 2 (TFPI2) -0.01954 -0.04471 0.005625 0.0062 
Toll-like receptor 3 (TLR3) 0.04275 0.01960 0.06589 <.0001 
Transforming growth factor alpha (TGF alpha) 0.07339 0.000477 0.1463 0.0075 
Transforming growth factor beta receptor type 2 
(TGFR2) 
0.02914 0.008093 0.05019 0.0226 
Tumour necrosis factor (TNF) receptor 
superfamily member 9 (TNFRSF9) 
0.03568 0.008146 0.06322 0.0001 
Vascular endothelial growth factor A (VEGF-A) 0.02176 -0.00999 0.05352 0.0047 
WNT1-inducible signalling pathway protein 1 
(WISP-1) 
0.10061 0.07561 0.1256 <.0001 
s100-A11 0.03298 -0.03280 0.09876 0.0006 
The estimate for month denotes the average slope of the linear trend over time, i.e. how much the average protein value 
changes over one month (a positive value indicates an increase over time). A false discovery rate of 10% was applied. All p-










































Figure 1. Proteins significantly different between non-relapse and relapse cases. The mean protein 
levels were estimated by a linear trend over time, and these linear trends were compared between 
the two groups in a linear mixed effects model. The mean protein levels are displayed as a solid blue 
line while individual patient values are shown in dotted coloured lines. Red circles indicate where 
relapses occurred. A false discovery rate of 10% was applied. A) Leukaemia inhibitory factor receptor 
(LIF-R), B) IL-15 receptor alpha C) Colony stimulating factor 1 (CSF-1), D) Transforming growth factor 
beta receptor type 2 (TGFR-2), E) Stem cell factor (SCF) and F) Folate receptor alpha (FR alpha).  
Figure 2. Proteins significantly different between imatinib and dasatinib treated patients. Thin 
vertical lines represent mean values and error bars represent the standard deviation. A) Monocyte 
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Appendix A. Supplementary data 
Supplemental Table A1. All analytes, Inflammation I. 
Adenosine Deaminase (ADA) FGF-23 Monocyte chemotactic protein 
(MCP)-1 
Artemin (ARTN) Fms-like tyrosine kinase 3 
ligand (Flt3L) 
MCP-2 
Axin-1 Glial cell line-derived 




Hepatocyte growth factor 
(HGF) 
MCP-4 
Beta-nerve growth factor 
(Beta-NGF) 
Interferon (IFN)-gamma Macrophage inflammatory 
protein (MIP)-1 alpha 
Caspase (CASP)-8 Interleukin (IL)-1-alpha Matrix metalloproteinase 
(MMP)-1 
C-C motif chemokine (CCL)4 IL-2 MMP-10 
CCL11 IL-4 Neurturin (NRTN) 
CCL19 IL-5 Neurotrophin (NT)-3 
CCL20 IL-6 Osteoprotegerin (OPG) 
CCL23 IL-7 Oncostatin-M (OSM) 
CCL25 IL-8 Programmed death ligand 1 
(PD-L1) 
CCL28 IL-10 Stem cell factor (SCF) 
Cluster of differentiation (CD)5 IL-12B SIR2-like protein 2 (SIRT2) 
CD6 IL-13 Signaling lymphocytic 
activation molecule 1 
(SLAMF1) 
CD40 IL-17A STAM-binding protein 
(STAMPB) 
CD244 IL-17C Sulfotransferanse (ST)1A1 
CUB domain-containing 
protein 1 (CDCP1) 
IL-18 S100-A12 (EN-RAGE) 
Colony stimulating factor 
(CSF)-1 
IL-20 Transforming growth factor 
(TGF)-alpha 
Cystatin D (CST5) IL-24 Tumour necrosis factor (TNF) 
C-X-C motif chemokine(CXCL)1 IL-33 TNFB 
CXCL5 IL-2 receptor (R)B TNF-receptor superfamily 
member 9 (TNFRSF9) 
CXCL6 IL-10RA TNF-ligand superfamily 
member 14 (TNFSF14) 
CXCL9 IL-10RB TNF-related apoptosis-inducing 
ligand (TRAIL) 
CXCL10 IL-15RA TNF-related activation-induced 
cytokine (TRANCE) 
CXCL11 IL-18R1 Thymic stromal lymphopoietin 
(TSLP) 
Fractalkine (CX3CL1) IL-20RA TNF-ligand superfamily 
member 12 (TWEAK) 
Delta- and notch-like 
epidermal growth factor-
IL-22-RA1 Urokinase-type plasminogen 
activator (uPA) 
Supplementary Materials
related receptor (DNER) 
Fibroblast growth factor (FGF)-
5 
Latency associated peptide 
transforming growth factor 
(LAP TGF)-beta-1 
Vascular endothelial growth 
factor (VEGF)-A 
FGF-19 Leukemia inhibitory factor (LIF) Eucaryotic translation initiation 
factor 4E-binding protein (4E-
BP1) 
FGF-21 LIF-R  
      
      
      
   
Supplemental Table A2. All analytes, Oncology II.  
Tyrosine-protein kinase 1 
(ABL1) 
Folate receptor (FR)-alpha Proto-oncogene tyrosine-
protein kinase receptor Ret 
(RET) 
A disintegrin and 
metalloproteinase domain-
containing protein (ADAM) 8 
FR-gamma R-spondin 3 (RSPO3) 




Furin (FUR) Secretory carrier-associated 
membrane protein 3 (SCAMP3) 
Annexin A1 (ANXA1) Galectin (Gal)-1 SCF 
Amphiregulin (AR) Glypican 1 (GPC1) Seizure 6-like protein (SEZ6L) 
Carbonic anhydrase (CA)9 Glycoprotein NMB (GPNMB) SPARC 
CD27 Granzyme (GZM)B  Syndecan 1 (SYND1) 
CD48 GZMH S100-A4 
CD70 Kallikrein (hK)8 S100-A11 
CD160 hK11 T cell leukemia/lymphoma 
protein (TCL)1A 
CD207 hK14 Tissue factor pathway inhibitor 
(TFPI)-2 
Cyclin-dependent kinase 
inhibitor 1 (CDKN1A) 
ICOS ligand (ICOSLG) TGF-alpha 
Carcinoembryotic antigen-
related cell adhesion molecule 
(CEACAM)1 
IFN-gamma-R1 TGFR-2 
CEACAM5 Insuline-like growth factor 1 
receptor (IGF1R) 
Toll-like receptor (TLR)3 
Carboxypeptidase E (CPE) IL-6 TNFSF13 
Cornulin (CRNN) Integrin alpha-V (ITGAV) TNFRSF4 
Cathepsin L2 (CTSV) Integrin beta-5 (ITGB5) TNFRSF6B 
CXCL13 Kallikrein (KLK)13 TNFRSF19 






protein 3 (LYPD3) 
Taxilin alpha (TXLNA) 
Delta-like protein 1 (DLL1) Lymphocyte antigen 9 (LY9) VEGF-A 












regulatory protein (MIA) 
Vimentin (VIM) 
Receptor protein-tyrosine 
kinase ErbB (ERBB)2 
MHC class I polypeptide-
related sequence A/B (MIC-
A/B) 
WAP four-disulfide core 
domain protein (WFDC)2 
ERBB3 Midkine (MK) Wnt inhibitory facot (WIF)-1 
ERBB4 Mesothelin (MSLN) Wnt1-inducible-signaling 
pathway protein (WISP)-1 
Fas-associated death domain 
protein (FADD) 
Mucin (MUC)-16 Xaa-pro aminopeptidase 2 
(XPNPEP2) 
Fas antigen-ligand (FASL) Podocalyxin (PODXL)  n cle ida e 5'-NT) 
Fc-receptor-like B (FCRLB) Pancreatic pro-hormone (PPY)  
Fibroblast growth factor-
binding protein 1 (FGF-BP1) 
Nectin-4 (PVRL4)  
  
 
 
